Stockscreener 앱 받기
0.5656
0.70%
0.0051
전일 마감가:
$0.5707
열려 있는:
$0.57
하루 거래량:
89,225
Relative Volume:
0.10
시가총액:
$33.62M
수익:
$2.06M
순이익/손실:
$-19.80M
주가수익비율:
-0.7852
EPS:
-0.7203
순현금흐름:
$-20.12M
1주 성능:
+8.84%
1개월 성능:
+17.29%
6개월 성능:
+46.57%
1년 성능:
-60.64%
1일 변동 폭
$0.5601
$0.575
1주일 범위
$0.49
$0.59
52주 변동 폭
$0.3067
$1.7599
Femasys Inc Stock (FEMY) Company Profile
명칭
Femasys Inc
전화
770-500-3910
주소
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, RMD, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.565 | 33.96M | 2.06M | -19.80M | -20.12M | -0.7203 |
|
ISRG
Intuitive Surgical Inc
|
484.96 | 175.03B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
161.87 | 46.42B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
79.27 | 39.37B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
RMD
Resmed Inc
|
235.66 | 34.98B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
41.35 | 34.41B | 28.43B | 1.16B | 1.26B | 1.4457 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | Laidlaw | Buy |
Femasys Inc 주식(FEMY)의 최신 뉴스
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing - MSN
Femasys begins enrollment in pivotal trial for FemBloc device By Investing.com - Investing.com South Africa
Femasys begins enrollment in pivotal trial for FemBloc device - Investing.com Nigeria
Non-surgical permanent birth control FemBloc begins final U.S. trial - Stock Titan
Femasys Inc. (NASDAQ:FEMY) Receives $5.50 Average Price Target from Analysts - Defense World
Lake Street initiates Femasys stock coverage with buy rating By Investing.com - Investing.com Australia
Lake Street initiates Femasys stock coverage with buy rating - Investing.com
FEMY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FEMY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
FEMY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Femasys’s FemBloc Pivotal Trial Update: What Investors Should Watch in Women’s Health - TipRanks
Femasys Announces FemBloc® Permanent Birth Control Has - GlobeNewswire
New non-surgical permanent birth control clears key global quality hurdle - Stock Titan
Femasys Announces FemBloc Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access - Bitget
Sentiment Watch: Is Femasys Inc stock undervalued right nowJuly 2025 Setups & Low Risk Investment Opportunities - baoquankhu1.vn
Femasys receives CPT code approval for infertility treatment - Investing.com India
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Femasys receives CPT code approval for infertility treatment By Investing.com - Investing.com South Africa
Trend Review: Can Femasys Inc benefit from deglobalization2025 Big Picture & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
AMA procedure code supports new infertility option for over 10M US women - Stock Titan
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - Bitget
Femasys (FEMY) CEO awarded 729,000 RSUs vesting through 2027 - Stock Titan
Femasys (NASDAQ: FEMY) CFO receives 342,000 restricted stock units - Stock Titan
Femasys (FEMY) CTO reports common stock and option holdings in Form 3 - Stock Titan
How cyclical is Femasys Inc.’s revenue streamJuly 2025 News Drivers & Technical Pattern Based Buy Signals - mfd.ru
Femasys : Shareholder Update – 2025 in Review - marketscreener.com
Can Femasys Inc. sustain its profitabilityJuly 2025 Weekly Recap & Risk Managed Investment Strategies - mfd.ru
Forecast Cut: What dividend growth rate does Femasys Inc offerMarket Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Femasys stock rises on new distribution partnership in Switzerland By Investing.com - Investing.com Australia
Femasys expands European presence with Swiss distribution deal By Investing.com - Investing.com Nigeria
Femasys Inc. Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products - marketscreener.com
Femasys stock rises on new distribution partnership in Switzerland - Investing.com
Femasys expands European presence with Swiss distribution deal - Investing.com
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products - The Manila Times
Femasys Inc. Expands European Presence with New Distribution Partnership in Switzerland - Quiver Quantitative
Insider Sell: Is Omega Healthcare Investors Inc subject to activist investor interest2025 Major Catalysts & Smart Investment Allocation Tips - baoquankhu1.vn
Trading Action: Can Femasys Inc sustain its profitabilityTake Profit & Accurate Entry/Exit Alerts - baoquankhu1.vn
Femasys Secures Major Order for FemBloc Launch - MSN
Travel Stocks: What is PCARs revenue forecastEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Returns Recap: Does Ares Management Corporation meet Warren Buffetts criteria2025 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
Femasys Receives Nasdaq Extension to Regain Listing Compliance - The Globe and Mail
Femasys granted 180-day extension by Nasdaq to meet minimum bid price rule - Investing.com
Femasys Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Stock Recap: Will FUFU benefit from geopolitical trendsCPI Data & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Sahm
Femasys receives 180-day Nasdaq extension to meet minimum bid price - Investing.com Nigeria
Femasys Inc (FEMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
자본화:
|
볼륨(24시간):